CONGRESS|#EHA2021|Katja Weisel, University Hospital Hamburg presented results from GMMG CONCEPT trial for high risk pts primary established Isa-KRd quadruplet treatment in NDMM, PFS rate of 79.6% &75.5% obtained after12 & 24 months respectively #mmsm #myeloma pic.twitter.com/5J0rQz54fm
— Multiple Myeloma Hub (@MM_Hub) June 14, 2021